An 8-week Randomized, Double-blind, Placebo-controlled Factorial Study to Evaluate the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Essential Hypertension
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 20 Oct 2015
Price : $35 *
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Amlodipine
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 04 Aug 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 29 Jan 2014 Planned initiation date changed from 1 Oct 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov record.
- 29 Jan 2014 Status changed from recruiting to not yet recruiting as reported by ClinicalTrials.gov record.